GLP-1yog encoded los ntawm glucagon noob (GCG) thiab yog cleaved los ntawm protease PC1/3 los ua ob daim ntawv nquag: GLP-1 (7-36) amide (80%) thiab GLP-1 (7{23}}37) (20%). Lub qub yog lub ntsiab active daim ntawv, thaum lub tom kawg kuj muaj lom lom tom qab amidation. Txawm li cas los xij, ntuj GLP-1 muaj qhov tsis muaj zog txaus: nws yooj yim cleaved thiab inactivated los ntawm DPP-4 ntawm N-terminal alanine txoj hauj lwm 2, nrog ib nrab-lub neej ntawm plasma tsawg dua 2 feeb. Tsis tas li ntawd, nws tuaj yeem tshem tawm sai sai ntawm lub raum. Nws yog qhov tseeb no "kev tsis haum xeeb" uas tau yuam ob lub tswv yim tshuaj loj: GLP-1 receptor agonists (GLP-1 RAs) - uas tiv thaiv DPP-4 degradation los ntawm kev hloov kho cov qauv; DPP-4 inhibitor - ncua lub sijhawm ua haujlwm ntawm endogenous GLP-1 los ntawm inhibiting degradation enzymes.
1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-1-187
GLP -1 7-37 CAS 106612-94-6
Cov mis mos molecular: C151H228N40O47
Molecular Luj: 3355.67
Chaw tsim tshuaj paus: BLOOM TECH Wuxi Hoobkas
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Lub khw tseem ceeb: Tebchaws Asmeskas, Australia, Brazil, Nyiv, Lub Tebchaws Yelemees, Indonesia, UK, New Zealand, Canada thiab lwm yam.
Peb muab GLP-1, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia tshwj xeeb thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/synthetic-chemical/api-kev tshawb nrhiav-only/glp-1-7-37-peptide.html
Lub ntiaj teb thawj GLP-1 gene therapy tau pom zoo rau kev siv tshuaj kho mob
Thaum Lub Tsib Hlis 11, 2026, Fractyl Health tshaj tawm tias nws tau txais kev pom zoo rau daim ntawv thov kev kho mob hauv Netherlands thiab yuav tshaj tawm thawj tus neeg sib tw tshuaj RJVA-001 ntawm nws Rejuvea Smart GLP-1 gene therapy platform! / Thawj tib neeg kev sim tshuaj.
RJVA-001 yog ib qho -lub sijhawm tsom rau kev kho noob rau pancreatic beta hlwb, uas tuaj yeem ua tiav lub cev tso tawm ntawm GLP-1 nrog rau kev noj zaub mov hauv pancreas, thiab xav kom zam ntau yam kev mob tshwm sim los ntawm kev siv tshuaj ntau dhau hauv kev kho GLP-1. Cov tshuaj no ncaj qha nkag mus rau hauv cov ntaub so ntswg los ntawm kev siv tshuab endoscopic minimally invasive endoscopic ultrasound-guided thev naus laus zis, tso siab rau lub tuam txhab tus kheej tsim thiab hloov kho tib neeg cov tshuaj insulin txhawb nqa thiab thauj cov teeb liab los txhawb GLP-1 secretion hauv transduced pancreatic islet hlwb tom qab pub mis.
RJVA-001 yog lub ntiaj teb thawj tus kab mob adeno-associated virus (AAV) gene therapy rau hom 2 mob ntshav qab zib kom nkag mus rau theem kho mob, thiab tseem yog lub ntiaj teb thawj GLP-1 gene therapy nkag mus rau theem kho mob. Lub tuam txhab npaj yuav ua kom tiav kev tswj hwm ntawm RJVA-001 thawj tus neeg mob hauv ib nrab xyoo 2026, thiab tso tawm cov ntaub ntawv tshawb fawb ua ntej.
Pfizer tau txais kev ua haujlwm ntev ntev GLP-1 receptor agonists tau pom zoo rau kev sim tshuaj hauv Suav teb thawj zaug
Thaum Lub Tsib Hlis 12, 2026, lub vev xaib raug cai ntawm Tuam Tshoj National Center for Drug Evaluation (CDE) tshaj tawm tias Pfizer's Class 1 cov tshuaj tshiab PF-08653944 Kev txhaj tshuaj tau raug pom zoo rau kev siv tshuaj kho mob ntev rau cov neeg laus nrog qhov pib lub cev qhov hnyav (BMI) ntawm 228 kg / m2 (qhov hnyav tshaj 228 kg / m2) thiab qhov hnyav tshaj (228 kg / m2). ib qho hnyav txog qhov teeb meem (xws li hyperglycemia, kub siab, hyperlipidemia, obstructive pw tsaug zog apnea, kab mob plawv, thiab lwm yam), raws li kev tswj hwm kev noj haus thiab kev tawm dag zog ntxiv. Cov ntaub ntawv pej xeem qhia tau hais tias qhov no yog thawj zaug PF-08653944 tau txais kev pom zoo hauv Suav teb.
Siv
Ua ntej, cov piam thaj nyob ntawm kev nce qib ntawm insulin secretion. GLP-1 receptor ua haujlwm rau ntawm qhov chaw ntawm pancreatic beta hlwb ua rau cAMP PKA teeb liab txoj hauv kev, txhim kho insulin synthesis thiab tso tawm. Qhov tseem ceeb yog tias qhov kev txhawb nqa no nruj me ntsis nyob ntawm cov ntshav qab zib - nws tsuas yog siv zog thaum cov ntshav qab zib siab dua 5 mmol / L, thiab yuav nres thaum cov ntshav qab zib zoo li qub. Yog li ntawd, siv GLP-1RA ib leeg yuav tsis tshua ua rau cov ntshav qab zib tsawg, uas yog nws cov txiaj ntsig kev nyab xeeb tseem ceeb piv rau cov tshuaj sulfonylurea.
Qhov thib ob, inhibit qhov tso tawm ntawm glucagon. Los ntawm kev ua haujlwm ntawm cov kab mob pancreatic alpha uas nyob ib sab los ntawm paracrine secretion, nws inhibits qhov tso tawm ntawm glucagon, txo qis glycogen hauv lub siab thiab gluconeogenesis, thiab ua ke txo qis ntshav qab zib los ntawm "qhib qhov chaw" kawg.
Thirdly, ncua lub plab khoob. Ua haujlwm ntawm cov phab ntsa hauv plab thiab cov hlab ntsha vagus afferent fibers, ua rau qeeb qeeb ntawm cov ntsiab lus ntawm plab hnyuv tawm mus rau hauv duodenum. Qhov no mechanism tsis tsuas yog smooths tawm lub ntse nce nyob rau hauv postprandial ntshav qab zib, tab sis kuj prolongs lub cev satiety, ua rau nws yog ib qho tseem ceeb contributors rau nws yuag poob.
